 |
Board of Directors
Robbie Melton is the Program Manager for Entrepreneurial
Development at the Maryland Technology Development Corporation (TEDCO). Robbie
works directly with technology start up companies to determine the viability and worthiness
of the firm for candidacy for TEDCO funding programs and assists companies with other
investment opportunities and business needs. She serves on review committees for a
number of state funded technology programs and is a director of the MIT Enterprise
Forum Board. Robbie has nearly 20 years experience in managing technology development
and commercialization projects in a broad range of technologies. For five years she
was the operations manager for the Center for Cancer and Transplantation Biology at
the Children's National Medical Center. Robbie holds a Master's degree in Science,
Technology and Public Policy from The George Washington University.
Cynthia Wong Hu is
Vice President, General Counsel and Secretary of EntreMed, Inc. She is primarily responsible for
managing all aspects of EntreMed's legal activities, including transactions and compliance,
management of our external legal services, and interactions with EntreMed's Board.
Ms. Hu has also been appointed by the Board as Secretary and as an executive officer
of the Company. Prior to joining EntreMed, she served as a senior attorney for the
business finance practice group at Powell Goldstein LLP, in Washington, DC., where
she advised clients with regard to public and private financing transactions, partnership
and operating agreements, various corporate agreements, mergers and acquisitions,
SEC compliance matters, stock and asset purchase agreements and general corporate
matters. Before that, Ms. Hu served as internal counsel for Golden American Life
Insurance Company focusing on filings and compliance with the Securities Act of 1933
and the Investment Company Act of 1940. She is also a Director of Strathmore Hall
Foundation, Inc. Ms. Hu received her J.D. from Rutgers University School of Law
in 1994 and is admitted to the Bar in
New York
,
Pennsylvania
and the
District of
Columbia
.
Phyllis Dillinger is the Executive Vice President
and C.F.O. of KPL. KPL manufactures and
distributes antibodies and reagents to the Life Science Research community. During
her 11 years with KPL, Ms. Dillinger completed a divestiture, spun off a separate
Genomics business and most recently relocated the organization to a 30,000 square
foot state of the art facility. Prior
to joining KPL, she was C.F.O. of Sopha Medical the French held U.S. subsidiary manufacturing
gamma cameras for 10 years. During her
stay at Sopha, sales grew from $1M to $42M. She completed a $85M dollar merger between
Sopha Medical and Summit Vision and relocated the new organization to
Cleveland
,
Ohio
. Ms. Dillinger holds an M.B.A. from The
George Washington University
Sue Hendrickson is a Partner in the Intellectual
Property and Technology Practice Group of Arnold & Porter LLP. Her practice
focuses on technology-related transactions and the protection, development, transfer
and commercialization of intellectual property assets. Ms. Hendrickson routinely
represents pharmaceutical, biotech, medical device and other life sciences companies
in connection with their commercial arrangements. She has advised on life sciences
transactions involving all phases of the product life cycle, from early research,
development and financing efforts, through clinical trials, product approval, manufacturing,
marketing and commercialization and next generation product development. Among
other matters, she has represented pharmaceutical and other life sciences companies
in connection with licensing transactions, research and development agreements, clinical
trial agreements, co-promotion and co-marketing agreements, feasibility and proof
of concept studies, distribution agreements, manufacturing and supply arrangements,
strategic alliances, product acquisitions and divestitures and other commercial arrangements.
Shira Kramer, Ph.D., is the President and a Founder of the Sterilex
Corporation. She holds a Ph.D. in Epidemiology, a Masters degree in Human Genetics,
and a Bachelors degree in Biochemistry, all from The Johns Hopkins University. Dr.
Kramer formed the Sterilex Corporation in 1995, with the goal of developing and marketing
novel antimicrobial products that are designed to overcome the factors responsible
for antimicrobial resistance. Sterilex current technology platform targets bacterial
biofilm, and the companys patented products are used in health and dental care, food
processing, water treatment, and industrial applications. Sterilex is the proud
recipient of the Technology Council of Maryland 2004 Bio Product of the Year Award.
Prior to her activities at Sterilex, Dr. Kramer, in 1984, founded RidgeCom,
Inc., an epidemiological research and consulting firm. At RidgeCom, Dr. Kramer
conducted a wide variety of epidemiological studies for industry (petroleum, chemical,
and pharmaceutical companies); academic institutions; and governmental
agencies. From 1978-1985, Dr. Kramer served as a member of the faculty at the
University of Pennsylvania School of Medicine, and directed an epidemiological research
program to identify risk factors for childhood cancers at the Childrens Hospital of
Philadelphia. During that time, she published numerous articles on the epidemiology
and etiology of childhood cancers, published two textbooks on epidemiologic methods,
and taught graduate-level courses in epidemiology.
Susan Mack is a senior partner at the intellectual property law firm
of Sughrue Mion, PLLC., where she is a member of the chemical, the biotechnology and
pharmaceutical, the nanotechnology, and the interference groups. Susan counsels
clients in all aspects of patent practice. She lectures in a variety of areas, including
chemical and pharmaceutical patent practice, the laws pertaining to generic
and brand name drugs, and nanotechnology patent practice. She holds a masters degree
in biophysics and genetics from the University of Colorado Health Science Center and
a juris doctorate from The American University, Washington college of Law.
Carol Nacy, Ph.D. was Executive Vice President and CSO at EntreMed,
Inc. from 1993 through its successful public offering in June 1996. She left
EntreMed in November 1996 to establish Sequella, Inc. and was part-time CSO (1997-98)
for Anergen, Inc., a California company focused on autoimmune diseases. There, she
reorganized the scientific staff and approach and positioned the company for acquisition
by Corixa Corp. in December 1998. Dr. Nacy became a full-time CEO and Chair
of Sequella and began drawing salary in January 1999. She is a member of the
Board of Directors of several companies(ASMResources, TolerGenics, Social and Scientific
Systems) and non-profit agencies (Sequella Foundation, Women in BIO). Before
her business experience, she was a Career Scientist and Science Manager at the Walter
Reed Army Institute of Research and the National Institutes of Health for seventeen
years.
Loleta M. Robinson is director, medical science,
at MedImmune, Inc. in
Gaithersburg
,
Maryland
. In this role she is responsible for identifying, developing and maintaining collaborative
relationships within the medical community. She communicates medical and scientific
information to ensure that healthcare providers are fully engaged and have
current, pertinent product, research
and healthcare policy information as well as appropriate training regarding use of
MedImmune's products.
Previously Dr. Robinson worked as the medical director for Thermo Electron's Point
of Care and Rapid Diagnostics Division in
Denver
,
Colorado
. She received a B.A. in microbiology
from the
University
of
Kansas
, an M.D. from the University of Kansas School of Medicine and an M.B.A. in Health
Administration from the
University
of
Colorado
.
|